Addyi

The National Women’s Health Network Expresses Profound Disappointment With FDA’s Decision to Approve Controversial Sex Drug.

By NWHN Staff | Aug 19, 2015 | Comments Off on The National Women’s Health Network Expresses Profound Disappointment With FDA’s Decision to Approve Controversial Sex Drug.

FOR IMMEDIATE RELEASE Contact: Christina Cherel at ccherel@nwhn.org or (202) 682-2640

Sex Drugs for Women: Myths and Marketing Messages

By Coco Jervis | Aug 7, 2015 | Comments Off on Sex Drugs for Women: Myths and Marketing Messages

Learn about 5 common myths surrounding sex drugs like Addyi and Viagra as well as the FDA’s approach to this issue.

National Women’s Health Network Urges the FDA to Oppose Twice-Rejected Female Sex Drug

By Cindy Pearson | Jun 3, 2015 | Comments Off on National Women’s Health Network Urges the FDA to Oppose Twice-Rejected Female Sex Drug

FOR IMMEDIATE RELEASE 
Contact: Cindy Pearson at 301-938-0356 or Coco Jervis at 202-407-0788

FDA to Consider Controversial Female Sexual Dysfunction Drug for the Third Time

By NWHN Staff | Jun 1, 2015 | Comments Off on FDA to Consider Controversial Female Sexual Dysfunction Drug for the Third Time

Over the last five years the National Women’s Health Network has, on numerous occasions, weighed in on the Food and Drug Administration’s (FDA) review of flibanserin, a drug intended to treat female sexual dysfunction.

You Can Count on Us

By NWHN Staff | Jun 1, 2015 | Comments Off on You Can Count on Us

Let’s face it, nearly all of us have had challenges with our sex lives at one time or another. And no wonder! We live in a culture that is obsessed with women’s sexuality and sexual performance and the pharmaceutical industry certainly wants to cash in on it.

The FDA’s Hesitation to Approve ‘Female Sexual Dysfunction’ Drugs Isn’t About Sexism

By Coco Jervis | Mar 27, 2015 | Comments Off on The FDA’s Hesitation to Approve ‘Female Sexual Dysfunction’ Drugs Isn’t About Sexism

The cultural impact and huge profitability of male-targeted impotence drugs has prompted a rapidly accelerating race to create similar drug treatments for women. Despite more than a decade of research and millions of dollars spent on development, the Food and Drug Administration (FDA) has yet to approve a single drug treatment for cis women dealing with so-called female sexual dysfunction (FSD).